### Edgar Filing: RIOUX PATRICE - Form 4

RIOUX PATRIC Form 4												
September 26, 20								OMB A	PPROVAL			
FORM 4	UNITED	STATES					COMMISSION	OND	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or Form 5	Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange							Number: Expires: Estimated burden hou response	January 31, 2005 average ırs per			
obligations may continue. <i>See</i> Instruction 1(b).	Section 17(	(a) of the	Public U	Itility Hol	ding Cor		of 1935 or Section					
(Print or Type Respon	nses)											
1. Name and Address of Reporting Person * 2. Issuer Name and   RIOUX PATRICE Symbol   Raptor Pharmaceu					Issuer							
(Last)	(First) (	Middle)	•	of Earliest T			) (Che	eck all applicabl	e)			
C/O RAPTOR 09/22/2011 PHARMACEUTICAL CORP., 9 COMMERCIAL BLVD., SUITE 200			Tunsuetion		below)	re title X_Othere of the other of the other othe	title 10% Owner Other (specify below) aptor Therapeutics					
NOVATO, CA 9	Street) 04949			endment, D onth/Day/Yea	-	1	6. Individual or . Applicable Line) _X_ Form filed by Form filed by Person		erson			
(City) (	State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned			
	ansaction Date th/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Reminder: Report on	a separate line	e for each cl	lass of sec	urities bene	ficially ow	ned directly o	or indirectly.					
					inforn requi	nation cont red to respo ays a curre	spond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	EC 1474 (9-02)			
	Tab					posed of, or convertible s	Beneficially Owned securities)	1				
1. Title of 2.	3. Trans	saction Date	e 3A. Dee	emed	4.	5. Number	of 6. Date Exerc	cisable and	7. Title and Amoun			

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Underlying Securitie

Expiration Date

#### Edgar Filing: RIOUX PATRICE - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Stock options (right to buy)	\$ 5.13	09/22/2011		A	37,872	03/22/2012 <u>(1)</u>	09/21/2012	Common stock	37,8
Stock options (right to buy)	\$ 5.13	09/22/2011		A	113,616	03/22/2012(1)	09/21/2012	Common stock	113,0

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
RIOUX PATRICE C/O RAPTOR PHARMACEUTICAL CORP. 9 COMMERCIAL BLVD., SUITE 200 NOVATO, CA 94949				CMO, Raptor Therapeutics		
Signatures						
/s/ Kim R. Tsuchimoto, CFO, Raptor Pharmaceut Attorney-in-fact		09/26/2011				
<u>**</u> Signature of Reporting Person			1	Date		

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Stock options vest 6/48ths on March 22, 2012 and 1/48th per month thereafter.

#### **Remarks:**

Dr. Rioux is the Chief Medical Officer of Raptor Therapeutics Inc., an indirect wholly-owned subsidiary of Raptor Pharmaceu

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.